The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial

L Zhang; J Coombes; Elaine Pascoe; V Badve Sunil; Dalziel Kim; Alan Cass; P Clarke; Paolo Ferrari; Stephen McDonald; Alicia Morrish; Eugenie Pedagogos; Vlado Perkovic; Donna Reidlinger; Anish Scaria; Rowan Walker; Liza Vergara; Carmel Hawley; David Johnson

doi:10.1179/1351000215Y.0000000022

The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial

L Zhang, J Coombes, Elaine Pascoe, V Badve Sunil, Dalziel Kim, Alan Cass, P Clarke, Paolo Ferrari, Stephen McDonald, Alicia Morrish, Eugenie Pedagogos, Vlado Perkovic, Donna Reidlinger, Anish Scaria, Rowan Walker, Liza Vergara, Carmel Hawley, David Johnson

Wellbeing and Preventable Chronic Disease

Research output: Contribution to journal › Article › peer-review

7 Downloads (Pure)

Abstract

Objective: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients.

Methods: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities.

Results: Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD −6.06 U/l, P = 0.09), or protein carbonyls (MD −0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04).

Conclusions: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.

Original language	English
Pages (from-to)	14-23
Number of pages	10
Journal	Redox Report
Volume	21
Issue number	1
DOIs	https://doi.org/10.1179/1351000215Y.0000000022
Publication status	Published - 2016

Access to Document

10.1179/1351000215Y.0000000022

5234361-oaFinal published version, 853 KB

Cite this

Zhang, L., Coombes, J., Pascoe, E., Sunil, V. B., Kim, D., Cass, A., Clarke, P., Ferrari, P., McDonald, S., Morrish, A., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, L., Hawley, C., & Johnson, D. (2016). The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Report, 21(1), 14-23. https://doi.org/10.1179/1351000215Y.0000000022

@article{e9cad4953a4c4d419059cda4b29d2788,

title = "The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial",

abstract = "Objective: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients.Methods: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities.Results: Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD −6.06 U/l, P = 0.09), or protein carbonyls (MD −0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04).Conclusions: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.",

author = "L Zhang and J Coombes and Elaine Pascoe and Sunil, {V Badve} and Dalziel Kim and Alan Cass and P Clarke and Paolo Ferrari and Stephen McDonald and Alicia Morrish and Eugenie Pedagogos and Vlado Perkovic and Donna Reidlinger and Anish Scaria and Rowan Walker and Liza Vergara and Carmel Hawley and David Johnson",

year = "2016",

doi = "10.1179/1351000215Y.0000000022",

language = "English",

volume = "21",

pages = "14--23",

journal = "Redox Report",

issn = "1743-2928",

publisher = "Maney Publishing",

number = "1",

}

Zhang, L, Coombes, J, Pascoe, E, Sunil, VB, Kim, D, Cass, A, Clarke, P, Ferrari, P, McDonald, S, Morrish, A, Pedagogos, E, Perkovic, V, Reidlinger, D, Scaria, A, Walker, R, Vergara, L, Hawley, C & Johnson, D 2016, 'The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial', Redox Report, vol. 21, no. 1, pp. 14-23. https://doi.org/10.1179/1351000215Y.0000000022

TY - JOUR

T1 - The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness

T2 - Sub-study of the HERO trial

AU - Zhang, L

AU - Coombes, J

AU - Pascoe, Elaine

AU - Sunil, V Badve

AU - Kim, Dalziel

AU - Cass, Alan

AU - Clarke, P

AU - Ferrari, Paolo

AU - McDonald, Stephen

AU - Morrish, Alicia

AU - Pedagogos, Eugenie

AU - Perkovic, Vlado

AU - Reidlinger, Donna

AU - Scaria, Anish

AU - Walker, Rowan

AU - Vergara, Liza

AU - Hawley, Carmel

AU - Johnson, David

PY - 2016

Y1 - 2016

N2 - Objective: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients.Methods: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities.Results: Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD −6.06 U/l, P = 0.09), or protein carbonyls (MD −0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04).Conclusions: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.

AB - Objective: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients.Methods: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities.Results: Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD −6.06 U/l, P = 0.09), or protein carbonyls (MD −0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04).Conclusions: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.

UR - http://www.scopus.com/inward/record.url?scp=84978699362&partnerID=8YFLogxK

U2 - 10.1179/1351000215Y.0000000022

DO - 10.1179/1351000215Y.0000000022

M3 - Article

C2 - 26083328

SN - 1743-2928

VL - 21

SP - 14

EP - 23

JO - Redox Report

JF - Redox Report

IS - 1

ER -

The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial

Abstract

Access to Document

Other files and links

Fingerprint

Cite this